Quantifying the treatment goals of people recently diagnosed with schizophrenia using best-worst scaling

被引:28
作者
Bridges, John F. P. [1 ]
Beusterien, Kathleen [2 ]
Heres, Stephan [3 ]
Such, Pedro [4 ]
Sanchez-Covisa, Joaquin [5 ]
Nylander, Anna-Greta [4 ]
Chan, Elcie [6 ]
de Jong-Laird, Anne [5 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
[2] Outcomes Res Strategies Hlth, Albemarle St NW, Washington, DC 20008 USA
[3] Tech Univ Munich, Dept Psychiat & Psychotherapy, Munich, Germany
[4] H Lundbeck A S, Global Med Affairs, Valby, Denmark
[5] Otsuka Pharmaceut Europe Ltd, Med Dept, Wexham, England
[6] Otsuka Pharmaceut Europe Ltd, HEOR Market Access, Wexham, England
关键词
recent-onset schizophrenia; preferences; treatment goals; PREFERENCES; BURDEN; ONSET; ANTIPSYCHOTICS; DISORDERS; BRAIN; AGE;
D O I
10.2147/PPA.S152870
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: This study seeks to quantify the treatment goals of people recently diagnosed with schizophrenia and explore their impact on treatment plan. Methods: People aged 18-35 years with a confirmed diagnosis of schizophrenia within the past 5 years were surveyed in the UK, Germany, and Italy. Treatment goals were assessed via a validated best-worst scaling instrument, where participants evaluated subsets of 13 possible treatment goals identified using a balanced incomplete block design. Participants identified the most and least important goals within each task. Data were also collected on current treatment and preference for daily oral versus long-acting injectable (LAI) treatment. Hierarchical Bayes was used to identify preference weights for the goals, and latent class analysis was used to identify segments of people with similar goals. The segments were compared with the current treatment and preference for oral versus LAI treatment. Results: Across 100 participants, the average age was 26 years, 75% were male and 50% were diagnosed within 2 years ago. Overall, preferences were most favorable for reduced disease symptoms, think clearly, reduced hospitalizations, reduced anxiety, and take care of self. A total of 61% preferred oral medication and 39% LAI. Two groups were identified with different treatment goals; 50% of participants emphasized clinical goals, including reduced disease symptoms (preference weight = 19.7%), reduced hospitalizations (15.5%), and reduced anxiety (10.5%). The other 50% emphasized functional goals, including improved relationships with family/friends (11.4%), increased interest in work (10.6%), experiencing a fuller range of emotions (8.4%), and ability to socialize (7.5%). Those emphasizing functional goals were more likely to be on LAI (44% versus 26%; p=0.059) and preferred LAI (46% versus 32%; p=0.151). Conclusions: People with recent-onset schizophrenia may focus more on clinical goals or functional goals, a discussion of which may help facilitate patient engagement.
引用
收藏
页码:63 / 70
页数:8
相关论文
共 38 条
[1]  
Barbato A., 1998, SCHIZOPHRENIA PUBLIC
[2]   Development of a stated-preference instrument to prioritize treatment goals in recent onset schizophrenia [J].
Beusterien, Kathleen ;
Chan, Elcie ;
Such, Pedro ;
Laird, Anne de Jong ;
Heres, Stephan ;
Amos, Kaitlan ;
Loze, Jean-Yves ;
Nylander, Anna-Greta ;
Robinson, Paul ;
Bridges, John F. P. .
CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (12) :2129-2136
[3]   Use of best-worst scaling to assess patient perceptions of treatments for refractory overactive bladder [J].
Beusterien, Kathleen ;
Kennelly, Michael J. ;
Bridges, John F. P. ;
Amos, Kaitlan ;
Williams, Mary Jo ;
Vasavada, Sandip .
NEUROUROLOGY AND URODYNAMICS, 2016, 35 (08) :1028-1033
[4]   A test of concordance between patient and psychiatrist valuations of multiple treatment goals for schizophrenia [J].
Bridges, John F. P. ;
Slawik, Lara ;
Schmeding, Annette ;
Reimer, Jens ;
Naber, Dieter ;
Kuhnigk, Olaf .
HEALTH EXPECTATIONS, 2013, 16 (02) :164-176
[5]  
Caroli F, 2011, PATIENT PREFER ADHER, V5, P165, DOI [10.2147/PPA.S15337, 10.2147/PPA.515337]
[6]   Global economic burden of schizophrenia: a systematic review [J].
Chong, Huey Yi ;
Teoh, Siew Li ;
Wu, David Bin-Chia ;
Kotirum, Surachai ;
Chiou, Chiun-Fang ;
Chaiyakunapruk, Nathorn .
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2016, 12 :357-373
[7]   Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study [J].
Decuypere, Flore ;
Sermon, Jan ;
Geerts, Paul ;
Denee, Tom R. ;
De Vos, Cedric ;
Malfait, Bart ;
Lamotte, Mark ;
Mulder, Cornelis L. .
PLOS ONE, 2017, 12 (06)
[8]   Enhancing Clients' Communication Regarding Goals for Using Psychiatric Medications [J].
Deegan, Patricia E. ;
Carpenter-Song, Elizabeth ;
Drake, Robert E. ;
Naslund, John A. ;
Luciano, Alison ;
Hutchison, Shari L. .
PSYCHIATRIC SERVICES, 2017, 68 (08) :771-775
[9]   The concept of progressive brain change in schizophrenia: Implications for understanding schizophrenia [J].
DeLisi, Lynn E. .
SCHIZOPHRENIA BULLETIN, 2008, 34 (02) :312-321
[10]   What matters to patients? A systematic review of preferences for medication-associated outcomes in mental disorders [J].
Eiring, Oystein ;
Landmark, Brynjar Fowels ;
Aas, Endre ;
Salkeld, Glenn ;
Nylenna, Magne ;
Nytroen, Kari .
BMJ OPEN, 2015, 5 (04)